NCT00403052View on ClinicalTrials.gov

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Colorectal Neoplasms
Interventions
DRUG

1018 ISS immunostimulatory oligonucleotide

6 weekly subcutaneous (under the skin) injections

Trial Locations (3)

20007

Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.

20817

Center for Cancer and Blood Disorders, Bethesda

90404

Premiere Oncology, Santa Monica

Sponsors
All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY